Real‐world Progression, Treatment, and Survival Outcomes During Rapid Adoption of Immunotherapy for Advanced Non–small Cell Lung Cancer

Cancer - United States
doi 10.1002/cncr.32383
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

P2.01-12 Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Real World Treatment Patterns and Resource Use for Advanced Non-Small Cell Lung Cancer in Brazilian Private Institutions

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Real-World Data on Nivolumab Treatment of Non-Small Cell Lung Cancer

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2016English

Potential Role of Immunotherapy in Advanced Non-Small-Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2016English

Post-Progression Survival After EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

PLoS ONE
Multidisciplinary
2015English

Pcn61 - Real-World Progression-Free Survival of Patients With Advanced Non-Small Cell Lung Cancer: Results of a Claims Data Study of Patients in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Maintenance Therapy Improves Survival Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

Lung
PulmonaryRespiratory Medicine
2015English

Latest Immunotherapy Methods in Non-Small Cell Lung Cancer Treatment

Juntendo Medical Journal
2019English

Real-World Costs of Laboratory Tests for Non-Small Cell Lung Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy